Inhibition of hepatic gluconeogenesis by FGF15/19 was previously observed in rodents8,36, and we found in the liver of CKD mice that FGF19 treatment reduced the expression of G6pc1, the rate limiting enzyme of gluconeogenesis. This evidence concerns the gene G6PC1 and chronic kidney disease.